NED
REGN icon

Nancy E. Dempze’s Regeneron Pharmaceuticals REGN Stock Holding History

Nancy E. Dempze’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$386K Sell
500
-200
-29% -$153K 0.21% 68
2025
Q4 		$540K Hold
700
– – 0.28% 58
2025
Q3 		$394K Sell
700
-100
-13% -$56.5K 0.22% 66
2025
Q2 		$420K Sell
800
-40
-5% -$22.3K 0.24% 66
2025
Q1 		$533K Sell
840
-120
-13% -$82.5K 0.32% 62
2024
Q4 		$684K Hold
960
– – 0.39% 56
2024
Q3 		$1.01M Sell
960
-140
-13% -$156K 0.56% 49
2024
Q2 		$1.16M Buy
+1,100
New +$1.07M 0.79% 36

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Nancy E. Dempze's REGN Position: Q1 2026 in Review

Nancy E. Dempze reduced its Regeneron Pharmaceuticals (REGN) stake by 29% in Q1 2026, selling an estimated $153K and leaving 500 shares worth $386K. The position accounts for 0.21% of the portfolio, ranked #68.

Nancy E. Dempze first reported a position in REGN in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.16M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Nancy E. Dempze held 500 shares of Regeneron Pharmaceuticals worth $386K as of Q1 2026.
  • Nancy E. Dempze sold 200 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $153K.
  • Regeneron Pharmaceuticals made up 0.21% of Nancy E. Dempze's portfolio in Q1 2026, its #68 holding.
  • Nancy E. Dempze first reported a position in Regeneron Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Nancy E. Dempze's Regeneron Pharmaceuticals position peaked at $1.16M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Nancy E. Dempze's 13F filing for Q1 2026, filed 14 May 2026.